Will Reblozyl Shine in Bristol Myers' Fourth-Quarter Results?

Key Takeaways BMY's growth portfolio, led by Reblozyl, is expected to support top-line growth in upcoming quarterly results.Reblozyl sales hit $1.66B in the first nine months of 2025, rising 35% year over year on strong demand.BMY faces revenue pressure as generic competition continues to erode sales of legacy brands.Bristol Myers’ (BMY) is banking on its growth portfolio, which comprises Opdivo, Orencia, Yervoy, Reblozyl, Opdualag, Abecma, Zeposia, Breyanzi, Camzyos, Sotyku, Krazati and others, to drive to ...